Krystal Biotech, Inc. (NASDAQ:KRYS) Short Interest Update

Krystal Biotech, Inc. (NASDAQ:KRYS) was the target of a significant decline in short interest during the month of January. As of January 15th, there was short interest totalling 3,370,000 shares, a decline of 8.9% from the December 31st total of 3,700,000 shares. Based on an average daily volume of 247,300 shares, the short-interest ratio is currently 13.6 days.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $164.78, for a total value of $4,119,500.00. Following the sale, the insider now directly owns 1,475,882 shares in the company, valued at $243,195,835.96. The trade was a 1.67 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 14.10% of the company’s stock.

Hedge Funds Weigh In On Krystal Biotech

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Wilmington Savings Fund Society FSB purchased a new position in Krystal Biotech in the third quarter worth $40,000. Values First Advisors Inc. bought a new stake in Krystal Biotech during the third quarter worth about $53,000. GAMMA Investing LLC boosted its holdings in shares of Krystal Biotech by 184.8% in the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the company’s stock worth $78,000 after purchasing an additional 279 shares in the last quarter. Huntington National Bank increased its position in shares of Krystal Biotech by 97.6% during the 3rd quarter. Huntington National Bank now owns 573 shares of the company’s stock valued at $104,000 after purchasing an additional 283 shares during the last quarter. Finally, Blue Trust Inc. raised its holdings in shares of Krystal Biotech by 242.4% during the 3rd quarter. Blue Trust Inc. now owns 582 shares of the company’s stock valued at $107,000 after buying an additional 412 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a research note on Wednesday, December 18th. Chardan Capital reiterated a “buy” rating and set a $212.00 price objective on shares of Krystal Biotech in a research note on Wednesday, December 18th. Finally, Citigroup lifted their target price on Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $206.67.

Krystal Biotech Stock Down 1.9 %

Shares of NASDAQ KRYS opened at $156.71 on Monday. The stock’s 50-day simple moving average is $165.65 and its two-hundred day simple moving average is $179.28. Krystal Biotech has a twelve month low of $107.50 and a twelve month high of $219.34. The firm has a market capitalization of $4.51 billion, a P/E ratio of 88.48 and a beta of 0.84.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The company had revenue of $83.84 million for the quarter, compared to analysts’ expectations of $82.94 million. During the same period in the prior year, the business earned ($0.67) earnings per share. Krystal Biotech’s revenue for the quarter was up 879.9% compared to the same quarter last year. As a group, research analysts anticipate that Krystal Biotech will post 3.22 EPS for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).